DEFA14A: Enhabit Management Discusses Strategic Priorities, Payer Innovation, and Growth Outlook at Healthcare Conferences

Enhabit's management team provided updates on their strategic priorities, payer innovation initiatives, and growth outlook at recent healthcare conferences.

Summary

• Enhabit's management team participated in the Leerink Partners Healthcare Crossroads Conference 2024 and the Goldman Sachs 45th Annual Global Healthcare Conference.
• They discussed the company's strategic alternatives process, expressing confidence in the current board of directors.
• A key focus is on payer innovation, with 64 new contracts secured since the spin-off, including two national agreements.
• Enhabit aims to stabilize its Medicare fee-for-service mix and grow its home health business by adding frontline clinicians and securing more favorable payer contracts.
• Hospice care is focused on stabilizing clinical staff, building out sales teams, and expanding through de novo locations.
• The company is targeting 10 de novo locations per year and has opened 15 since 2022.
• Enhabit is focused on improving clinical efficiency through tools like Medalogix Pulse and Muse, aiming for a 5% reduction in visits per episode.
• Management anticipates midto high-single-digit growth for both home health and hospice over the next three years.
• The company is prioritizing deleveraging and generating strong free cash flow.
• Corporate costs are expected to run at a rate of $27 million to $28 million per quarter.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting successful strategies, growth prospects, and financial stability. While acknowledging challenges, management expresses confidence in the company's ability to navigate the evolving healthcare landscape.

Positives

• Successful payer innovation strategy with 64 new contracts and 30 in the pipeline.
• Stabilization of the clinical workforce and elimination of contract labor.
• Focus on clinical efficiency and productivity improvements.
• Strong free cash flow generation and commitment to deleveraging.
• Positive employee engagement and recognition as a top place to work.
• Growth in non-Medicare revenue per visit.
• Sequential monthly growth in hospice census.
• Expansion through de novo locations.

Negatives

• Pressure on Medicare fee-for-service rates due to inflationary costs.
• Mix shift from Medicare fee-for-service to Medicare Advantage with lower payments.
• Uncertainty regarding future Medicare reimbursement rates.
• Potential for delays in contract negotiations and credentialing.
• High turnover rate among nurses within the first six months of employment.

Risks

• Regulatory changes and potential cuts in Medicare reimbursement rates.
• Inability to negotiate favorable payer contracts.
• Challenges in attracting and retaining qualified healthcare professionals.
• Competition from other home health and hospice providers.
• Economic downturn impacting patient volumes and payer mix.
• Potential disruptions or breaches of information systems.

Future Outlook

Enhabit anticipates midto high-single-digit growth for both home health and hospice over the next three years, driven by payer innovation, clinical capacity, and demographic trends. The company expects to continue generating significant free cash flow and prioritizes deleveraging.

Management Comments

• We're really confident in the slate that we have. We feel like we have a strong, very experienced board of directors.
• We've been able to increase our candidate pool by about 30% this year over last year in the first quarter.
• We've reached the point now where we are beginning to renegotiate historic contracts.
• We continue to believe that growth is a very important part of the long-term strategy.
• I'm most excited to have the year continue to progress.
• I'm excited about the success that we're seeing, the stabilization of EBITDA and what that will mean to our leverage, to our performance, to our earnings, to our free cash flow.

Industry Context

The announcements reflect the ongoing shift in the home health and hospice industry towards managed care and value-based payment models. Enhabit's focus on payer innovation and clinical efficiency aligns with industry trends aimed at managing costs and improving patient outcomes. The aging population and increasing preference for aging in place continue to drive demand for home-based care services.

Comparison to Industry Standards

• Enhabit's efforts to manage the shift from fee-for-service to Medicare Advantage are consistent with strategies employed by other major players in the home health industry, such as LHC Group (now part of Optum) and Amedisys.
• The company's focus on reducing visits per episode aligns with industry-wide initiatives to improve efficiency and reduce costs, similar to programs implemented by Kindred at Home (also part of Gentiva).
• Enhabit's de novo strategy is a common approach for expanding market presence, comparable to the growth strategies of companies like Addus HomeCare.
• The company's target of 10 de novo locations per year is similar to the expansion plans of other large home health and hospice providers.
• Enhabit's efforts to improve employee engagement and retention are in line with industry best practices, as labor shortages remain a significant challenge for home health and hospice providers.

Stakeholder Impact

• Shareholders: Focus on growth, profitability, and deleveraging aims to enhance shareholder value.
• Employees: Emphasis on employee engagement and retention seeks to create a positive work environment.
• Patients: Commitment to high-quality care and expanding access to home-based services benefits patients and their families.
• Referral Sources: Building strong relationships and offering comprehensive services aims to meet the needs of referral sources.
• Payers: Focus on value-based care and cost-effectiveness seeks to align incentives with payers.

Next Steps

• Continue to negotiate and implement new payer contracts.
• Focus on improving clinical efficiency and productivity.
• Expand through de novo locations.
• Monitor and respond to regulatory changes.
• Prioritize deleveraging and free cash flow generation.

Key Dates

Keywords

home health, hospice, payer innovation, Medicare Advantage, fee-for-service, clinical workforce, de novo, reimbursement, contracts, Medalogix, growth, EBITDA, census